**miR-219 Regulates Liver Cancer Stem Cell Expansion via E-cadherin pathway**

Anfeng Si1,#, Longqi Wang2,#, Kun Miao3,#, Rongrong Zhang4, Huiyu Ji1, Zhengqing Lei5, Zhangjun Cheng5, Xiangchun Fang1,\*, Baobing Hao1,\*

1Department of Surgical Oncology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu, China

2Department of General Surgery I, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu, China

3Oncology Dept. Ward, Tianchang People's Hospital, Anhui, China

4Department of General Surgery III, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu, China

5Department of General Surgery, the Affiliated Zhongda Hospital, Southeast University, Nanjing, China.

#These authors contributed equally to this work

**\*Correspondence author address:**

Dr. Xiangchun Fang, Department of Surgical Oncology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu, China. Tel: 0086-25-80864770; Fax: 0086-25-80864770; E-mail: safesurgery@sina.com; or Baobing Hao, MD, Department of Surgical Oncology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu, China. Tel: 0086-25-80864730; Fax: 0086-25-80864730; E-mail: bing110615@163.com.

**Running title:** miR-219 promotes liver cancer stem cell expansion

**Abbreviations:** HCC: Hepatocellular carcinoma; CSCs: cancer stem cells; DMEM: Dulbecco's modified Eagle’s medium; FBS: fetal bovine serum; OS: overall survival.

**Funding information:** This work was supported by the grand from the State Key Project on Infectious Diseases of China (2018ZX10732202-003)

**Supplementary Table**

**Supplementary Table 1. Clinicopathological features of 48 HCC patients**

|  |  |  |  |
| --- | --- | --- | --- |
| Characteristics |  |  | Total n=48 |
| Age(year) | ≤50 |  | 37 |
| >50 | 11 |
| Gender | Male | 45 |
| Female | 3 |
| HBsAg | Positive | 46 |
| Negative | 2 |
| AFP(μg/L) | ≤400 | 38 |
| >400 | 10 |
| Tumor size(cm) | ≤5 | 6 |
| >5 | 42 |
| Tumor number | Single | 25 |
| Multiple | 23 |
| Portal vein tumor thrombus | Yes | 5 |
| No | 43 |
| Pathological satellite | Yes |  | 17 |
| No |  | 31 |
| BCLC stage | A | 18 |
| B or C | 30 |
| TNM | I-II |  | 18 |
| I-II |  | 30 |